 After reporting second-quarter financials that beat industry watchers estimates, Medpace Holdings NASDAQ: MEDP shares are soaring 13.5 higher at 11:55 a.m. EDT on Tuesday. Investors were concerned revenue and profitability would be crimped by reduced clinical trial activity because of COVID-19 precautions. Safety measures limiting risk to clinical trial participants and workers did weigh down the healthcare companys second-quarter performance, but not nearly as badly as feared. 